RYR2-Related Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT1): Comprehensive Research Report

1. Disease Information

Overview. Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited primary arrhythmia syndrome ("channelopathy") characterized by exercise- or emotion-induced bidirectional or polymorphic ventricular tachycardia (VT) in individuals with a structurally normal heart and a normal resting electrocardiogram. It is one of the most lethal of the inherited arrhythmia syndromes if untreated, with syncope, cardiac arrest, or sudden cardiac death (SCD) — sometimes as the first manifestation — occurring characteristically during physical exertion or acute emotional stress (GeneReviews, NBK1289, updated 2022; PMID:20301466).

Key identifiers: - OMIM (phenotype): CPVT1, #604772 (with or without atrial dysfunction and/or dilated cardiomyopathy) — RYR2-related - OMIM (gene): RYR2 180902 - Related OMIM subtypes: CPVT2 #611938 (CASQ2, gene 114251); CPVT3 #614021 (TECRL, gene 617242); CPVT4 #614916 (CALM1, gene 114180); CPVT5 #615441 (TRDN, gene 603283); CPVT6 #618782 (CALM3, gene 114183) - Orphanet: ORPHA3286 (Catecholaminergic polymorphic ventricular tachycardia) - MONDO: MONDO:0011001 (catecholaminergic polymorphic ventricular tachycardia 1) is the RYR2-specific entity beneath the broader CPVT grouping term; MONDO integrates OMIM/Orphanet/ICD mappings for the umbrella and per-gene subtypes. - ICD-10: I47.2 (Ventricular tachycardia, unspecified — CPVT has no dedicated ICD-10 code and is typically captured under this or I49.0) - MeSH: Tachycardia, Ventricular (D017180); no CPVT-specific MeSH descriptor - HPO: HP:0004758 (Paroxysmal ventricular tachycardia) / HP:0004756 (bidirectional ventricular tachycardia, if modeling that specific ECG pattern); HP:0001279 (Syncope); HP:0001645 (Sudden cardiac death)

Synonyms: CPVT; Familial polymorphic ventricular tachycardia; Bidirectional ventricular tachycardia (historical, for the classic ECG pattern); Catecholamine-induced polymorphic ventricular tachycardia; "Stress-induced polymorphic ventricular tachycardia."

Evidence basis: Information is derived predominantly from aggregated disease-level resources — multicenter clinical registries (e.g., the PACES CPVT registry, PMID for multi-genetic-variant analysis PMC6221297), GeneReviews expert consensus, systematic reviews/meta-analyses of published cohorts, ClinVar/gnomAD population variant databases, and mechanistic studies in iPSC-cardiomyocytes and animal models — rather than from a single large EHR-based cohort, reflecting the disease's rarity.

2. Etiology

Disease Causal Factors. CPVT is purely genetic/mechanistic in etiology — a primary "electrical disease" of cardiomyocyte Ca²⁺ handling, with no infectious or classic environmental causal factor. The disease is triggered (not caused) by adrenergic surges (exercise, acute emotion, occasionally auditory stimuli or fever).

Genetic Risk Factors: - RYR2 (autosomal dominant, gain-of-function): causal in ~50–65% of clinically diagnosed CPVT (estimates range 50–70% across cohorts) (GeneReviews NBK1289; PMID:38542006). - CASQ2 (autosomal recessive, loss-of-function): ~2–5% of cases (CPVT2, OMIM #611938). - TRDN (autosomal recessive): <1–5% of cases (CPVT5). - CALM1/CALM2/CALM3 ("calmodulinopathy," predominantly de novo, autosomal dominant): <1–2% combined; produce a mixed LQTS/CPVT/overlap phenotype (PMID review, Tandfonline 2023). - TECRL (autosomal recessive): CPVT3, rare, combined CPVT/QT-prolongation phenotype. - KCNJ2: rare, associated with some CPVT-like presentations distinct from classic Andersen-Tawil syndrome. - Roughly ~25% of clinically diagnosed CPVT patients remain genetically unsolved after comprehensive panel testing (GeneReviews NBK1289). - De novo RYR2 variants account for an estimated 30–40% of RYR2-CPVT cases (no prior family history) (GeneReviews).

Environmental/Demographic Risk Factors: - Age: mean onset 7–12 years (childhood/adolescent onset is typical, though cases up to age 40 are reported). - Sex: male sex is a risk factor for earlier symptom onset and syncope/cardiac events in RYR2-CPVT — relative risk of syncope ~4.2 in men vs. women in some cohort analyses. - Physical exertion and competitive sports are the principal environmental precipitants; emotional stress is a secondary trigger. - Digitalis/digoxin is a specific pharmacologic risk factor — it favors DAD-mediated triggered arrhythmia and is explicitly listed as an agent to avoid.

Protective Factors: - No specific protective genetic variants are established; some RYR2 missense variants show markedly incomplete penetrance (a recent Bayesian penetrance-modeling study — medRxiv 2025.03.20.25324327 / PMC13108506 — reclassified variant risk using structural + population data), implying that certain domains/positions confer lower phenotypic risk even when "pathogenic" by ACMG criteria. - Nonselective beta-blockade (nadolol) is the major modifiable protective intervention (pharmacologic, not innate). - CYP2D6 pharmacogenetic variation affects propranolol clearance/efficacy (sex-dimorphic; testosterone upregulates CYP2D6, causing faster clearance/lower efficacy in men, partially explaining sex-based outcome differences).

Gene-Environment Interactions: The central GxE axis in CPVT is genotype (RyR2 leak threshold) × sympathetic/adrenergic state (exercise, emotion, occasionally fever). Beta-adrenergic stimulation via PKA/CaMKII phosphorylation of RyR2 lowers the store-overload-induced Ca²⁺ release (SOICR) threshold in already-destabilized mutant channels, converting a subclinical molecular lesion into life-threatening arrhythmia only under catecholamine surge — i.e., the genetic lesion is necessary but adrenergic environmental triggering is required for clinical events. A recent biorxiv 2025 preprint on CaMKII phosphorylation of RYR2 (2025.09.15.676430) reinforces CaMKII-dependent phosphorylation as "essential for arrhythmia in CPVT," a specific molecular GxE node.

3. Phenotypes

Age of onset: Mean 7–12 years; documented range from infancy (occasionally presenting as unexplained SIDS-associated RYR2 variants) to age 40. Severity/progression: Highly variable expressivity — some RYR2 carriers remain asymptomatic lifelong (~50% of mutation carriers per some series, reflecting incomplete penetrance), while others present with SCD as the sentinel event. Course is typically stable-to-episodic under treatment; without treatment, risk of events accumulates with age and continued exposure to exertional/emotional triggers, described as "80% cumulative cardiac events by age 40 if untreated" in some series. Quality of life: Activity restriction (competitive-sports contraindication) is the dominant QoL burden in children/adolescents; psychological burden of living with SCD risk and, in the neurodevelopmental subgroup, cognitive/behavioral impact are documented but not yet formally quantified with SF-36/EQ-5D instruments in the literature reviewed.

4. Genetic/Molecular Information

Causal gene: RYR2 (HGNC:10484; chromosome 1q43), encoding cardiac ryanodine receptor 2 (RyR2), the principal Ca²⁺-release channel of the sarcoplasmic reticulum (SR) in cardiomyocytes.

Variant landscape: - CPVT-causing RYR2 variants are overwhelmingly missense, clustering in defined "hotspot" domains: N-terminal domain (~aa 77–466), central domain (~aa 2246–2534), and the C-terminal channel/transmembrane and RyR/IP3R-homology-associated domains (~aa 3949–4332 and 4867–4967) (Nature/J Hum Genet PMID underlying s10038-020-0738-6; recent structural-penetrance paper PMC13108506/medRxiv 2025.03.20.25324327). - A large aggregation study identified 1,014 affected heterozygotes carrying 468 unique RYR2 missense variants among 622,575 total heterozygotes/5,181 unique variants pooled from literature and gnomAD, underscoring the scale of variant heterogeneity (medRxiv 2025.03.20.25324327). - Population frequency: pathogenic RYR2 CPVT variants are individually very rare in gnomAD (example cited frequency ~3/249,018 chromosomes, ~0.0012%), consistent with a highly penetrant Mendelian disease-gene model, though ACMG reclassification efforts have found meaningful false-positive rates — one systematic re-review of 326 RYR2 missense variants reclassified 55 (16.9%) of previously disease-associated variants as benign/likely benign using 2015 ACMG/AMP criteria. - Functional consequence: The dominant mechanism is gain-of-function — mutant RyR2 channels show increased open probability and heightened sensitivity to luminal/cytosolic Ca²⁺ activation, lowering the threshold for store-overload-induced Ca²⁺ release (SOICR) and producing diastolic SR Ca²⁺ leak. Rare loss-of-function RYR2 variants have also been described, producing a distinct phenotype of exertional syncope/ventricular fibrillation without inducible bidirectional VT on stress testing (Circ Arrhythm Electrophysiol, PMID for "Human RyR2 Loss-of-Function Mutations," CIRCEP.121.010013). - Germline, not somatic: CPVT is a germline Mendelian channelopathy; there is no COSMIC/somatic association. - Modifier genes: No robustly established modifier genes beyond the disease genes themselves; CaMKII-mediated phosphorylation status of RyR2 is a key post-translational/regulatory modifier of arrhythmic risk (biorxiv 2025.09.15.676430).

Recessive/other subtype genes: - CASQ2 (HGNC:1512; calsequestrin-2): loss-of-function, reduced Ca²⁺-buffering capacity and destabilized RyR2 macromolecular complex; 100% penetrant when biallelic; compound heterozygous CASQ2 variants reported with variable long-term course (PMID:29178653). - TRDN (HGNC:12261; triadin): recessive, reduces CASQ2 levels and impairs coupled Ca²⁺ release; may present with mild skeletal myopathy and T-wave inversions/QT prolongation (atypical CPVT). - CALM1/2/3 (calmodulin, HGNC:1442/1848/1849): identical protein product from 3 genes; reduced Ca²⁺-binding affinity impairs regulatory interactions with both CaV1.2 (→ LQTS phenotype) and RyR2 (→ CPVT-like phenotype). CALM-variant carriers present with LQTS (49%), CPVT (28%), overlap LQTS/CPVT (4%), or idiopathic VF/SUD in the remainder (Tandfonline 2023 review). - TECRL (trans-2,3-enoyl-CoA reductase-like): recessive, elevated diastolic Ca²⁺ and impaired mitochondrial function, combined CPVT+QT-prolongation phenotype (CPVT3, OMIM #614021).

Epigenetic information: No disease-defining epigenetic mechanism has been established for CPVT; the disorder is a classical monogenic ion-handling channelopathy.

Chromosomal abnormalities: Not applicable — CPVT is caused by point/small indel variants, not large structural/chromosomal rearrangements.

5. Environmental Information

• Environmental/toxic factors: No toxin, pollutant, or occupational exposure is implicated as causal; digitalis/digoxin is the principal pharmacologic environmental risk modifier (arrhythmia-promoting via DAD mechanism) and is explicitly listed as an agent to avoid.
• Lifestyle factors: Competitive/strenuous exercise and intense emotional stress are the dominant modifiable triggers — activity restriction is a cornerstone of management, not merely correlative.
• Infectious agents: None established as causal; some cohorts note fever as an occasional non-adrenergic trigger context, but this is not a primary infectious mechanism.

6. Mechanism / Pathophysiology

Causal chain (RYR2 gain-of-function, CPVT1):

1. Trigger: Sympathetic/adrenergic activation (exercise, emotion) → PKA and CaMKII phosphorylation of RyR2 and associated Ca²⁺-handling machinery.
2. Molecular lesion: Gain-of-function RYR2 missense variant destabilizes the closed-state conformation of the channel (disrupted N-terminal/central-domain interdomain interactions), lowering the SR luminal Ca²⁺ threshold required for spontaneous store-overload-induced Ca²⁺ release (SOICR) (PMC10311407 — "RYR2-ryanodinopathies: from calcium overload to calcium deficiency," EP Europace 2023).
3. Cellular consequence: Diastolic SR Ca²⁺ leak generates spontaneous, propagating intracellular Ca²⁺ waves in cardiomyocytes.
4. Electrophysiological consequence: Leaked cytosolic Ca²⁺ is extruded via the electrogenic Na⁺/Ca²⁺ exchanger (NCX, 3 Na⁺ in : 1 Ca²⁺ out), generating a net inward depolarizing current that manifests as a delayed afterdepolarization (DAD).
5. Arrhythmia trigger: When DAD amplitude reaches action-potential threshold, it triggers an ectopic beat; when this occurs from distinct/alternating ventricular foci (often Purkinje-adjacent) under ongoing adrenergic drive, the result is the classic bidirectional or polymorphic ventricular tachycardia, which can degenerate into ventricular fibrillation and sudden cardiac death (PMC6928245, PMC2704947).
6. A recent 2025 study specifically demonstrates that subthreshold DADs can still disrupt ventricular activation patterns even without reaching full AP threshold, broadening the arrhythmogenic mechanism beyond simple triggered-beat generation (PMC12221671, RyR2-R420Q model).

Cell types involved: Ventricular and Purkinje-fiber cardiomyocytes (primary); a growing body of evidence also implicates hippocampal/neocortical neurons, since RyR2 is the dominant RyR isoform in brain and its dysregulation is mechanistically linked to a neurodevelopmental/neurocognitive phenotype in a subset of RYR2-CPVT patients (Nature Communications Biology PMC/s42003-022-03124-2; Circ Arrhythm Electrophysiol 2024 CIRCEP.124.013437 reporting ~8% ID prevalence in 421 CPVT1 patients; medRxiv 2025.07.26.25332119 linking RyR2 calcium leak in patient-derived neurons to autism spectrum features). This has prompted a proposed reframing of CPVT as a "neurocardiac" condition in recent literature (biorxiv 2025.01.27.635037).

Suggested GO terms: - GO:0014808 (release of sequestered calcium ion into cytosol by sarcoplasmic reticulum) - GO:0086005 (ventricular cardiac muscle cell action potential) - GO:0086027 (SR-sarcolemma junction organization/ calcium release channel activity) - GO:0005219 (ryanodine-sensitive calcium-release channel activity) - GO:0002026 (regulation of the force of heart contraction)

Suggested CL terms: - CL:0002131 (cardiac ventricle myocyte) - CL:0002355 (cardiac Purkinje myocyte) - CL:0000540 (neuron) — for the emerging neurocardiac arm

Protein dysfunction: Gain-of-function conformational destabilization (not aggregation/misfolding in the classic proteotoxic sense) — mutant RyR2 favors a "leaky," hyperactive closed-to-open transition, well characterized by cryo-EM structural studies of specific CPVT mutants (e.g., R2474S) showing altered channel-gate conformations.

Metabolic changes: RyR2 is also expressed in pancreatic beta cells; altered glucose metabolism has been reported in some RYR2 carriers (GeneReviews NBK1289), an emerging but non-cardiac metabolic association.

Biochemical abnormality: The core lesion is an ion-channel (Ca²⁺ release channel) gating defect — a "channelopathy" in the strict sense, not an enzyme deficiency.

Advanced/omics findings: iPSC-cardiomyocyte disease modeling is the dominant functional-genomics platform for RYR2-CPVT (used extensively for drug screening — e.g., EL20 RyR2 inhibitor, PMC8366453). Structural cryo-EM reconstructions of mutant RyR2 channels (e.g., R2474S) directly visualize altered channel-gate conformations relative to wild-type.

7. Anatomical Structures Affected

• Organ level (primary): Heart — specifically ventricular myocardium and the cardiac conduction/Purkinje system; the heart is structurally normal by imaging (echocardiography/MRI), the defect being purely electrical.
• Secondary organ involvement: Brain (neurodevelopmental/cognitive phenotype in a subset of RYR2 patients); pancreas (beta-cell RyR2 expression, glucose-handling changes in some carriers); skeletal muscle (mild myopathy reported in TRDN-related CPVT).
• Body systems: Cardiovascular (primary); nervous system (emerging secondary/neurocardiac axis); endocrine/metabolic (minor, glucose handling).
• Tissue/cell level: Cardiac muscle tissue — ventricular cardiomyocytes and Purkinje fibers are the principal arrhythmogenic substrate (CL:0002131, CL:0002355); hippocampal and neocortical neurons for the neurologic phenotype.
• Subcellular level: Sarcoplasmic reticulum (GO:0005791/0033017 — SR membrane and junctional SR), specifically the RyR2 Ca²⁺-release channel complex at the SR-sarcolemma dyad/triad junction, and its regulatory partners FKBP12.6 (calstabin2), calsequestrin-2, triadin, and junctin.
• UBERON terms: UBERON:0002082 (cardiac ventricle); UBERON:0002080 (heart); UBERON:0001884 (Purkinje fiber); UBERON:0002421 (hippocampal formation).
• Lateralization: Not applicable — disease is a diffuse/bilateral electrical/molecular process affecting the whole ventricular myocardium, not a focal/lateralized lesion. (LCSD, notably, is performed unilaterally — usually left-sided — as a therapeutic intervention rather than reflecting disease lateralization.)

8. Temporal Development

• Onset: Typically pediatric/adolescent — mean age 7–12 years; documented range from infancy (occult RYR2 variants implicated in some SIDS cases) through age 40. Onset pattern is typically acute/paroxysmal (a syncopal or cardiac-arrest event), rather than insidious.
• Progression: Disease "stage" is not formally classified (unlike cancer staging), but clinical severity is tracked longitudinally via serial exercise stress testing and Holter monitoring; a 2025 medRxiv study specifically examined long-term serial exercise stress testing in CPVT patients on beta-blocker + flecainide therapy, showing the disease course and arrhythmia burden can be tracked and is modifiable by combination pharmacotherapy over years of follow-up.
• Progression rate/course: Without treatment, risk of life-threatening events accumulates with continued exposure to triggers (cumulative event rates reported as high as ~80% by age 40 in some untreated series); with beta-blocker ± flecainide therapy, the disease course is typically stabilized, though breakthrough events can still occur, particularly around puberty (dose titration to weight is emphasized) and with poor treatment adherence.
• Duration: Chronic, lifelong condition — there is no spontaneous resolution; the risk persists across the lifespan though relative event rates are highest in childhood/adolescence and young adulthood.
• Remission patterns: No spontaneous remission is described; symptomatic "remission" (arrhythmia suppression) is treatment-induced via beta-blockade, flecainide, LCSD, or combinations — assessed by serial provocative stress testing.
• Critical periods: Puberty is repeatedly flagged in the literature as a critical vulnerability window requiring more frequent surveillance and dose re-titration owing to rapid weight/body-composition change affecting drug dosing.

9. Inheritance and Population

Epidemiology: - Prevalence: Estimated at approximately 1 in 10,000 individuals (frequently cited range 1:10,000–1:15,000), though true prevalence is likely underestimated because patients have normal resting ECG and normal cardiac imaging, making ascertainment difficult except after a sentinel arrhythmic event or targeted family cascade screening. - Incidence data: No robust population-based incidence rate is established given underdiagnosis; the disease is best characterized via registry-based prevalence and familial-cascade detection.

Inheritance patterns: - Autosomal dominant: RYR2, CALM1, CALM2, CALM3, KCNJ2 — each affected parent transmits with 50% risk per offspring. - Autosomal recessive: CASQ2, TRDN, TECRL — 25% recurrence risk per sibling, 50% carrier risk. - De novo RYR2 variants explain an estimated 30–40% of RYR2-CPVT cases lacking family history.

Penetrance: - RYR2: Mean penetrance estimated at ~83% in some series, but with wide variant-to-variant heterogeneity; approximately 50% of mutation carriers may remain entirely asymptomatic, reflecting substantial incomplete/variable penetrance — a 2025 Bayesian structural-modeling paper specifically develops continuous, variant-level penetrance estimates for RYR2-CPVT missense variants rather than a single point estimate (PMC13108506/medRxiv 2025.03.20.25324327). - CASQ2 (biallelic): ~100% penetrant. - Heterozygous CASQ2 carriers may show a mild/subclinical phenotype. - Insufficient case numbers exist to derive robust penetrance estimates for CALM, KCNJ2, TRDN, and TECRL variants (GeneReviews NBK1289).

Expressivity: Variable — even within families carrying the identical RYR2 variant, phenotype severity ranges from asymptomatic to sudden death, and there is documented sex-based expressivity divergence (see below).

Genetic anticipation: Not a recognized feature of CPVT (not a repeat-expansion disorder).

Founder effects: The best-documented founder mutation is the Finnish RyR2-P2328S variant, traced by genealogical analysis to a common ancestor couple in central Finland in the 17th–18th century (PMC7735638). Other population-specific variant clusters have been reported (e.g., in Kazakh and Chinese cohorts) though without formal founder-effect confirmation in the sources reviewed.

Consanguinity: Relevant specifically for the recessive subtypes (CASQ2, TRDN, TECRL), where consanguineous unions increase biallelic-variant risk, consistent with general autosomal recessive disease principles.

Carrier frequency: Population carrier frequency of any single pathogenic RYR2 variant is very low (individual variant frequencies on the order of 0.001–0.01% in gnomAD), consistent with high aggregate genetic heterogeneity (>460 unique disease-associated missense variants described) rather than one or a few common alleles.

Population demographics: - No strong ethnic-specific prevalence enrichment is described beyond the Finnish founder cluster; the disease has been reported across European, East Asian (Chinese systematic review, PMC9330865), Central Asian (Kazakh cohort), and other populations. - Sex ratio: Not markedly skewed in genetic prevalence, but clinical expressivity is sex-dimorphic — males show earlier symptom onset and higher relative risk of syncope/cardiac events (RR ~4.2 in some analyses), partly attributable to CYP2D6-mediated sex differences in beta-blocker (propranolol) pharmacokinetics (testosterone-driven CYP2D6 upregulation → faster clearance/lower drug exposure in males). - Age distribution: Predominantly diagnosed in childhood/adolescence/young adulthood; a minority present later (up to age 40).

10. Diagnostics

Clinical diagnostic criteria (GeneReviews NBK1289; consensus HRS/EHRA/APHRS and ESC criteria): CPVT is diagnosed when there is (a) a structurally normal heart on imaging, (b) a normal resting ECG, and (c) exercise- or emotion-induced bidirectional or polymorphic VT; OR when a heterozygous pathogenic variant is found in RYR2/CALM1/CALM2/CALM3/CASQ2/KCNJ2, or biallelic variants in CASQ2/TECRL/TRDN.

Exercise stress testing: The primary provocative test — arrhythmia (PVCs progressing to bigeminy, couplets, then sustained bidirectional/polymorphic VT) typically emerges at a heart rate threshold of 90–120 bpm, with progressively increasing complexity as workload increases; positive in up to ~80% of symptomatic patients.

Epinephrine (catecholamine) challenge: Used when exercise testing is not feasible (young children) or symptoms are emotion-triggered. Standard protocol: incremental epinephrine infusion starting at 0.05–0.1 mcg/kg/min, increasing by 0.05 mcg/kg/min increments to a maximum of 0.20 mcg/kg/min; test is positive with induction of sustained/non-sustained polymorphic VT (>10 PVCs/min) or new T-wave alternans. Compared to exercise testing, epinephrine challenge has low sensitivity (~28%) but high specificity (~98%).

Holter monitoring: Alternative/complementary method, particularly for very young patients or emotion-triggered (non-exertional) presentations.

Genetic testing: Multigene panel (RYR2, CASQ2, CALM1-3, TRDN, TECRL, KCNJ2) or exome/genome sequencing is recommended as first-tier molecular testing; sequence-analysis detection sensitivity approaches 99–100% for most genes, though ~25% of clinically diagnosed patients remain molecularly unsolved. ACMG/AMP-based reclassification efforts have found meaningful rates of prior misclassification (16.9% of previously "disease-associated" RYR2 missense variants reclassified benign in one study), underscoring the importance of rigorous variant curation (ClinVar cross-checking, structural/functional evidence, penetrance modeling).

Imaging: Echocardiography and cardiac MRI are used primarily to exclude structural heart disease (e.g., ARVC, cardiomyopathy) rather than to positively diagnose CPVT; performed at baseline and roughly every 2 years during surveillance.

Differential diagnosis: - Short-coupled Torsade de Pointes (SC-TdP): polymorphic VT not clearly adrenergically triggered and lacking the bidirectional pattern; no established effective CPVT-type therapy. - Long QT syndrome type 1 (LQT1): exercise-triggered syncope overlaps clinically, but LQT1 shows a prolonged QT interval and does not reproduce inducible bidirectional VT on graded exercise testing (unless overlap calmodulinopathy). - Arrhythmogenic right ventricular cardiomyopathy (ARVC): shows structural myocardial abnormality on imaging, distinguishing it from CPVT's structurally normal heart. - Idiopathic ventricular fibrillation: relevant differential for RYR2 loss-of-function variant carriers, who may present with VF without the classic inducible bidirectional VT pattern.

Screening: Cascade family screening (clinical + genetic) is standard once a proband is identified, given up to 50% first-degree-relative transmission risk (dominant genes) and family history present in ~30% of probands.

11. Outcome/Prognosis

• Untreated mortality: Historically cited untreated mortality figures range widely across sources — approximately 30–50% by age 30–35, with some series reporting cardiac event rates as high as 80% by age 40 if untreated; approximately 30% experience cardiac arrest and up to 80% experience syncope if untreated (GeneReviews NBK1289).
• With treatment: Beta-blocker therapy (particularly nadolol) substantially reduces mortality and arrhythmic events; combination therapy (beta-blocker + flecainide ± LCSD/ICD) further reduces breakthrough events, as demonstrated in long-term serial-stress-testing follow-up cohorts (medRxiv 2025.04.08.25325493).
• Morbidity: Beyond mortality, morbidity includes recurrent syncope, ICD-related complications (inappropriate/ineffective shocks, which can paradoxically worsen VT storm via further adrenergic surge), and — in the RYR2-neurodevelopmental subgroup — intellectual disability and behavioral impact.
• Prognostic factors: Genotype (RYR2 vs. CASQ2 vs. calmodulinopathy), specific variant/domain location and structural severity (informing the new Bayesian penetrance models), sex (male sex worse), age at first event, and treatment adherence/response on serial exercise testing are the principal prognostic determinants identified in the literature. No single validated prognostic biomarker (analogous to a cancer biomarker) exists; risk stratification instead relies on genotype, clinical/family history, and provocative testing response.
• ICD-specific risk: ICDs are a double-edged prognostic tool in CPVT — while indicated in drug-refractory, highly symptomatic disease, inappropriate or even appropriate shocks can trigger further catecholamine release, precipitating an electrical storm; this is a well-recognized complication specific to this disease's adrenergic-arrhythmia mechanism.

12. Treatment

Pharmacotherapy (first-line): - Beta-blockers — nonselective agents preferred over cardioselective ones. Nadolol (1–2.5 mg/kg/day) is considered possibly superior; propranolol (2–4 mg/kg/day, divided) is a common alternative. NCIT: Pharmacotherapy (NCIT:C15986); therapeutic agent nadolol/propranolol (beta-adrenergic antagonists). - Flecainide (Class IC antiarrhythmic; 100–300 mg/day in adults) — added when beta-blockade alone is insufficient; reported effective in suppressing exercise-induced ventricular arrhythmia in ~75% of patients, with effect appearing largely independent of underlying genotype. NCIT: Chemotherapy is not applicable; use NCIT:C15986 Pharmacotherapy with therapeutic_agent flecainide (CHEBI).

Advanced/emerging therapeutics: - RyR2-targeted small molecules ("Rycals" and related stabilizers): JTV519 (K201) and S107 stabilize FKBP12.6 (calstabin2) binding to RyR2, reducing diastolic Ca²⁺ leak; dantrolene (a hydantoin derivative, historically a malignant-hyperthermia drug) has been repurposed and shown in iPSC-cardiomyocyte studies to reduce ectopic beats in a mutation/domain-dependent manner — more effective for N-terminal and central-domain RyR2 mutations than transmembrane-domain mutations, consistent with its proposed mechanism of stabilizing the N-terminal/central-domain interaction. Newer tetracaine-derivative RyR2 inhibitors (EL9, EL20) have shown efficacy in patient-derived iPSC-cardiomyocyte models (PMC8366453). A novel RyR2-selective stabilizer preventing stress-induced arrhythmia was reported in a 2024/2025 preprint (biorxiv 2024.11.26.625386). - Gene therapy: Solid Biosciences' AAV-based gene therapy candidate SGT-501 for CPVT began its first-in-human Phase 1b study in May 2024, an open-label trial enrolling approximately 43 patients aged 4–11 years — the first gene-therapy clinical trial specifically for CPVT (CGTlive, 2024). NCIT: Gene Therapy (NCIT:C15238).

Surgical/interventional: - Left cardiac sympathetic denervation (LCSD): Recommended as an adjunct in young patients not fully protected by beta-blockade, or when patients fail combination beta-blocker + flecainide therapy; also used to reduce ICD shock burden. Side effects include Horner-type ptosis and facial/arm anhidrosis. NCIT: Surgical Procedure (NCIT:C15329) or a sympathectomy-specific NCIT code if available. - Implantable cardioverter-defibrillator (ICD): Indicated in drug-refractory, highly symptomatic disease; use requires caution given the risk that shocks (appropriate or inappropriate) can provoke further catecholamine release and precipitate electrical storm, a distinctive management challenge in this specific arrhythmia syndrome. NCIT: Device (implantable cardioverter-defibrillator implantation).

Supportive/behavioral: - Absolute avoidance of competitive sports and strenuous exercise; activity restriction counseling. NCIT:C181743 (Behavioral Counseling) / therapeutic_modality: BEHAVIORAL. - Avoidance of digitalis/digoxin (arrhythmia-promoting). - Atropine has been studied experimentally in CPVT (registered trial NCT02927223) though it is not standard therapy and its precise role remains investigational.

Genetic counseling: Family cascade testing and counseling given 50% (dominant) or 25% (recessive) transmission risk; recommended given the potential for sudden death as first manifestation in unrecognized carriers.

Treatment algorithm (stepwise): (1) Beta-blocker (nadolol preferred) for all clinically affected individuals and asymptomatic pathogenic-variant carriers → (2) add flecainide if breakthrough arrhythmia on stress testing/symptoms → (3) LCSD and/or ICD if still refractory, with LCSD often favored first given the risk of ICD-triggered arrhythmic storms → (4) gene therapy (SGT-501) and novel RyR2 stabilizers under active clinical investigation as of 2024–2025.

13. Prevention

• Primary prevention: Not applicable in the classic sense (no modifiable non-genetic cause to prevent onset), but pre-symptomatic beta-blocker initiation in genotype-positive, phenotype-negative relatives identified through cascade screening functions as a primary preventive strategy against the first (potentially fatal) event.
• Secondary prevention: Family cascade genetic screening after proband identification; periodic exercise stress testing surveillance (every 6–12 months, more frequent during puberty) to detect breakthrough arrhythmia before a clinical event.
• Tertiary prevention: ICD implantation and LCSD in patients with established, drug-refractory disease to prevent recurrent/fatal events; combination pharmacotherapy adjustment based on serial stress-test results.
• Screening: No population-based newborn screening exists (CPVT is not detectable on a resting ECG); screening is instead cascade/family-based following proband diagnosis, using multigene panel testing.
• Genetic counseling: Central to prevention — informing reproductive decisions and triggering early beta-blocker initiation in asymptomatic carriers.
• Behavioral/public health intervention: Activity restriction guidance (avoidance of competitive sports) issued through cardiology/sports-cardiology clinical guidelines is the principal behavioral prevention lever.
• Prophylaxis: Prophylactic beta-blockade in all genotype-positive individuals regardless of symptom status is explicitly recommended in GeneReviews given the risk of sudden death as the first manifestation.

14. Other Species / Natural Disease

• Taxonomy: RYR2 orthologs are highly conserved across vertebrates (NCBI Taxon 9606 human; conserved in Mus musculus NCBITaxon:10090, Danio rerio NCBITaxon:7955, Sus scrofa NCBITaxon:9823, Ovis aries NCBITaxon:9940).
• Gene orthologs: Mouse Ryr2 (NCBI Gene: 20191); highly conserved functional domains across species enable cross-species modeling.
• Naturally occurring disease in other species: No well-established naturally occurring CPVT/RYR2 disease model was identified in dogs via OMIA in this search (the related but mechanistically distinct Boxer-dog arrhythmogenic right ventricular cardiomyopathy is caused by a STRN variant, not RYR2, and was historically — and now understood to be incorrectly — attributed in part to calstabin2/FKBP12.6 deficiency in earlier literature). No confirmed naturally occurring veterinary CPVT phenotype driven by spontaneous RYR2 variants was found in the searched sources.
• Comparative biology: The RyR2-mediated Ca²⁺-leak/DAD arrhythmia mechanism is evolutionarily conserved and reproducible across engineered animal models (mouse, zebrafish, pig, sheep), supporting strong translational validity of the induced (non-natural) models described below.
• Zoonotic potential: Not applicable — CPVT is a non-infectious, purely genetic disease with no transmission risk.

15. Model Organisms

Mouse models (most extensively characterized): - RyR2-R4496C knock-in mouse (corresponding to human R4497C): generated by homologous recombination in a fully penetrant human CPVT family variant; considered "the first RyR2 transgenic mouse model that recapitulates the main aspects of human CPVT" — mice show stress/catecholamine-induced ventricular arrhythmia and sudden death, with cellular studies showing enhanced SR Ca²⁺ release and DAD generation, and structural destabilization favoring a closed-to-open channel transition (leaky channel). - RyR2-P2328S knock-in mouse: models the Finnish founder mutation; shown to downregulate Nav1.5, producing an additional arrhythmic substrate in ventricular tissue (PMC4792352) — illustrating a secondary ion-channel remodeling mechanism beyond the primary RyR2 Ca²⁺-leak defect. - RyR2+/− (haploinsufficient) mouse: exhibits arrhythmogenic phenotypes resembling CPVT, used to model loss-of-function-associated arrhythmia. - Additional knock-in efforts (e.g., attempted Q3924E Ca²⁺-binding-site mutant mice, PMC11674951) illustrate ongoing efforts to model specific structural domains, though not all attempted knock-ins produce viable/faithful models. - Exon-3-deletion RyR2 mouse: models a specific human CPVT-associated exon-skipping/deletion variant (PMC3990712).

Zebrafish models: Used to study CALM-mutation-associated CPVT via overexpression approaches, successfully demonstrating cardiac arrhythmia phenotypes; zebrafish offer high-throughput in vivo screening advantages for CPVT drug discovery given transparent embryos and amenability to genetic manipulation.

Large animal models: Pigs and sheep are increasingly used as large-animal ventricular-arrhythmia models given closer anatomical/physiological resemblance to the human heart than rodents (more ethically/economically favorable than dog models); RYR2-specific engineered large-animal CPVT models are less mature than the mouse literature but are an active area per recent reviews (Biology 2026, 15040343).

Cellular/iPSC models: Patient-derived induced pluripotent stem cell-cardiomyocytes (iPSC-CMs) are now the dominant translational platform for RYR2/CASQ2-CPVT — used to validate calcium-handling defects, screen RyR2-stabilizing compounds (dantrolene, EL20, S107/JTV519 analogs), and, in a 2025 study, to link RyR2 calcium leak in patient-derived neurons to autism-spectrum features, directly bridging the cardiac and emerging neurodevelopmental phenotype (medRxiv 2025.07.26.25332119).

Model limitations: Mouse cardiac electrophysiology differs substantially from human (heart rate, ion channel repertoire), so while Ca²⁺-leak/DAD mechanisms are well recapitulated, absolute arrhythmia thresholds and some pharmacologic responses may not translate directly; iPSC-CM models lack full three-dimensional tissue architecture and autonomic innervation context, limiting their ability to model the whole-organism adrenergic trigger.

Applications: These models have been essential for (1) establishing the core Ca²⁺-leak/DAD mechanistic paradigm, (2) genotype-specific drug screening (e.g., domain-dependent dantrolene efficacy), (3) preclinical validation of RyR2-stabilizer and gene-therapy (AAV-CASQ2/RYR2) approaches prior to human trials such as SGT-501.

Summary of Key Ontology Term Suggestions

Sources

• GeneReviews: Catecholaminergic Polymorphic Ventricular Tachycardia
• Clinical and Molecular Characterization of Patients With CPVT (Priori et al., Circulation 2002)
• RYR2 Variants in CPVT Patients: Insights From Protein Structure and Clinical Data (Circ Arrhythm Electrophysiol 2025)
• RYR2-ryanodinopathies: from calcium overload to calcium deficiency (EP Europace 2023)
• Disruption of ventricular activation by subthreshold DADs in RyR2-R420Q CPVT
• Therapeutic approach for CPVT patients (EP Europace 2012)
• Left cardiac sympathetic denervation for CPVT and LQTS
• Catecholaminergic Polymorphic Ventricular Tachycardia: Clinical Characteristics, Diagnostic Evaluation and Therapeutic Strategies (J Clin Med 2024)
• CPVT: Advancing From Molecular Insights to Preclinical Models (JAHA 2024)
• PACES CPVT Registry: multiple genetic variants
• International Multicenter Evaluation of CASQ2-CPVT (Circulation 2021)
• Long-term Serial Exercise Stress Testing in CPVT (medRxiv 2025)
• Structural Evaluation of RYR2-CPVT Missense Variants and Bayesian Penetrance Estimates (2025)
• Classification and correlation of RYR2 missense variants (J Hum Genet)
• Efficacy of RyR2 inhibitor EL20 in iPSC-CMs from a CPVT patient
• Solid Biosciences' CPVT Gene Therapy SGT-501 Phase 1b (CGTlive, 2024)
• Genealogy and clinical course of CPVT caused by RyR2 P2328S (Finnish founder mutation)
• The RyR2-P2328S mutation downregulates Nav1.5
• Calmodulin Mutations in Human Disease (2023 review)
• Intellectual and Neurodevelopmental Delays in Pediatric CPVT (Circ Arrhythm Electrophysiol 2024)
• Linking the heart and the brain: Neurodevelopmental disorders in CPVT (Mayo Clinic)
• Patient-derived cells: mutated RyR2 calcium leak underlies ASD and inherited arrhythmias (medRxiv 2025)
• OMIM #604772 — CPVT1
• OMIM #611938 — CPVT2 (CASQ2)
• Human RyR2 Loss-of-Function Mutations (Circ Arrhythm Electrophysiol)
• Selected Large-Animal Models of Ventricular Arrhythmias (Biology, 2026)
• Arrhythmogenic right ventricular cardiomyopathy in Boxer dogs and calstabin2 deficiency
• CaMKII Phosphorylation of RYR2 is Essential for Arrhythmia in CPVT (bioRxiv 2025)

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

• Disease Name: RYR2 CPVT
• MONDO ID: (if available)
• Category: Genetic

Research Objectives

Please provide a comprehensive research report on RYR2 CPVT covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

• What is the disease? Provide a concise overview.
• What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
• What are the common synonyms and alternative names?
• Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

• Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
• Risk Factors:

  Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

• Genetic risk factors (causal variants, susceptibility loci, modifier genes)
• Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
• Protective Factors:

  Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

• Genetic protective factors (protective variants, modifier alleles)
• Environmental protective factors (diet, lifestyle, exposures that reduce risk)
• Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

  Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

• Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

  Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

• Pathogenic Variants:
• Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
• Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
• Variant type/class (missense, frameshift, nonsense, splice-site, structural)
• Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
• Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
• Functional consequences (loss of function, gain of function, dominant negative)
• Modifier Genes: Genes that modify disease severity or expression
• Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

  Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

• Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

  Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

• Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

  Search first: CDC databases, WHO, PubMed, NHANES

• Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

  Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

• Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

  Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

• Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

  Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

• Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

  Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

• Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

  Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

• Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

  Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

• Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

  Search first: PubMed, Gene Ontology, Reactome

• Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

  Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

• Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Molecular Profiling (if available):
• Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
• Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
• Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
• Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
• Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
• Advanced Technologies (if applicable):
• Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
• Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
• Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
• Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

• Organ Level:
• Primary organs directly affected
• Secondary organ involvement (complications, secondary effects)
• Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

  Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

• Tissue and Cell Level:
• Specific tissue types affected (epithelial, connective, muscle, nervous)
• Specific cell populations targeted (with Cell Ontology terms)

  Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

• Subcellular Level:
• Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

  Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

• Localization:
• Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
• Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

• Onset:
• Typical age of onset (congenital, pediatric, adult, geriatric)
• Onset pattern (acute, subacute, chronic, insidious)

  Search first: OMIM, Orphanet, HPO, PubMed

• Progression:
• Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
• Progression rate (rapid, slow, variable)
• Disease course pattern (episodic, relapsing-remitting, progressive, stable)
• Disease duration (self-limited, chronic lifelong)

  Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

• Patterns:
• Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
• Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

• Epidemiology:
• Prevalence (cases per 100,000 at given time)
• Incidence (new cases per 100,000 per year)

  Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

• For Genetic Etiology:
• Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
• Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
• Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
• Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
• Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
• Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
• Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
• Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
• Population Demographics:
• Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
• Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
• Geographic distribution of specific variants
• Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
• Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

• Clinical Tests:
• Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
• Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
• Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
• Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
• Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
• Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
• Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
• Genetic Testing:

  Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

• Overview of recommended genetic testing approach
• Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
• Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
• Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
• Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
• Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
• Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
• FISH > Search first: ClinVar, cytogenetics databases, PubMed
• Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
• Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
• Omics-Based Diagnostics (if applicable):
• RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
• Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
• Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
• Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
• Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
• Clinical Criteria:
• Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
• Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
• Screening:
• Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

• Survival and Mortality:
• Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
• Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
• Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
• Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
• Morbidity and Function:
• Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
• Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
• Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
• Disease Course:
• Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
• Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
• Prediction:
• Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
• Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

• Pharmacotherapy:
• Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
• Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
• Advanced Therapeutics:
• Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
• Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
• RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
• Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
• Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
• Surgical and Interventional:
• Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
• Supportive and Rehabilitative:
• Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
• Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
• Experimental:
• Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
• Treatment Outcomes:
• Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
• Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
• Treatment Strategy:
• Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
• Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
• Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

• Prevention Levels:
• Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
• Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
• Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
• Immunization: Vaccine strategies (if applicable)

  Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

• Screening and Early Detection:
• Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
• Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
• Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
• Behavioral Interventions: Lifestyle modifications to reduce risk

  Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

• Counseling: Genetic counseling (risk assessment, family planning guidance)

  Search first: NSGC resources, ACMG guidelines, GeneReviews

• Public Health:
• Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
• Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
• Prophylaxis: Preventive medications or procedures

  Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

• Taxonomy: Species affected (with NCBI Taxon identifiers)

  Search first: NCBI Taxonomy

• Breed: Specific breeds affected (with VBO identifiers if applicable)

  Search first: VBO (Vertebrate Breed Ontology)

• Gene: Orthologous genes in other species (with NCBI Gene IDs)

  Search first: NCBI Gene

• Natural Disease:
• Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
• Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
• Comparative Biology:
• Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
• Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
• Transmission (if applicable):
• Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
• Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

• Model Types:
• Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
• Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
• Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
• Genetic Models:
• Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
• Model Characteristics:
• Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
• Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
• Applications:
• Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
• Resources:
• Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

• Cite primary literature (PMID preferred) for all mechanistic and clinical claims
• Prioritize recent reviews and landmark papers
• Include direct quotes from abstracts where possible to support key statements
• Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Research report: RYR2-mediated catecholaminergic polymorphic ventricular tachycardia (RYR2-CPVT / CPVT1)

Scope and evidence types

This report focuses on RYR2-mediated catecholaminergic polymorphic ventricular tachycardia (CPVT1), integrating 2023–2024 narrative reviews, pediatric observational cohorts/series, mechanistic structural/physiology studies, and ClinicalTrials.gov interventional trial records. Evidence sources here are aggregated disease-level resources (reviews and cohorts) rather than EHR-derived single-patient records, except where explicitly noted as case series. (aggarwal2024catecholaminergicpolymorphicventricular pages 1-2, peltenburg2024prognosisandclinical pages 1-2, lee2024treatmentoutcomesin pages 1-2, jurisic2023catecholaminergicpolymorphicventricular pages 1-2)

Table: This table summarizes the core naming and identification fields for RYR2-mediated CPVT, including synonyms, causal gene, inheritance, triggers, and the principal diagnostic test. It is useful as a compact normalization artifact for a disease knowledge base entry.

1. Disease information

1.1 Concise overview (current understanding)

RYR2-mediated CPVT is an inherited cardiac arrhythmia syndrome characterized by adrenergically triggered ventricular arrhythmias—classically bidirectional or polymorphic ventricular tachycardia—occurring in the absence of structural heart disease and typically with a normal resting ECG. Clinical presentations include exercise- or emotion-triggered syncope and risk of sudden cardiac death. (aggarwal2024catecholaminergicpolymorphicventricular pages 1-2, peltenburg2024prognosisandclinical pages 1-2)

1.2 Identifiers (OMIM/Orphanet/ICD/MeSH/MONDO)

The retrieved literature set did not include OMIM, Orphanet, MeSH, ICD-10/ICD-11, or MONDO identifier pages/records, so these identifiers cannot be verified or cited from primary database sources within the current tool context. (Evidence gap in retrieved documents.)

1.3 Synonyms/alternative names

Common synonyms include CPVT, CPVT1, RYR2-CPVT, and catecholaminergic polymorphic ventricular tachycardia type 1. (aggarwal2024catecholaminergicpolymorphicventricular pages 2-4, peltenburg2024prognosisandclinical pages 1-2)

2. Etiology

2.1 Disease causal factors

Primary cause: germline pathogenic or likely pathogenic variants in RYR2, encoding the cardiac ryanodine receptor (RyR2), a sarcoplasmic reticulum (SR) Ca2+ release channel. The dominant mechanism emphasized in recent reviews is RyR2 dysfunction leading to diastolic SR Ca2+ leak and triggered arrhythmias under catecholaminergic stimulation. (aggarwal2024catecholaminergicpolymorphicventricular pages 2-4, peltenburg2024prognosisandclinical pages 1-2)

2.2 Risk factors

Genetic risk factors - Autosomal dominant inheritance is typical for RYR2-mediated CPVT. (aggarwal2024catecholaminergicpolymorphicventricular pages 2-4) - Variant class/type: Most pathogenic RYR2 variants associated with CPVT are missense and are described as gain-of-function (in one review, ~96% missense). (aggarwal2024catecholaminergicpolymorphicventricular pages 2-4) - Penetrance: Reviews summarize high but incomplete penetrance for RYR2-mediated disease, approximately ~75–80%. (aggarwal2024catecholaminergicpolymorphicventricular pages 2-4) - De novo variants are described as common in some monogenic RYR2 cases and associated with earlier and more severe phenotypes. (aggarwal2024catecholaminergicpolymorphicventricular pages 2-4, peltenburg2024prognosisandclinical pages 1-2)

Non-genetic/clinical risk factors (phenotype triggers) - Exercise and emotional stress are the dominant triggers, consistent with catecholamine-dependent arrhythmogenesis. (aggarwal2024catecholaminergicpolymorphicventricular pages 1-2, peltenburg2024prognosisandclinical pages 1-2)

2.3 Protective factors

Direct protective factors (genetic or environmental) were not explicitly identified/quantified in the retrieved sources.

2.4 Gene–environment interactions

A central, well-supported interaction is genotype (RYR2 dysfunction) × catecholaminergic environment (exercise/emotion, adrenergic stimulation) leading to arrhythmia provocation. (aggarwal2024catecholaminergicpolymorphicventricular pages 1-2, peltenburg2024prognosisandclinical pages 1-2)

3. Phenotypes

3.1 Core clinical phenotype spectrum (with onset, severity, progression)

Typical presentation: exertion- or emotion-triggered syncope; palpitations may occur; ventricular tachyarrhythmias can degenerate to ventricular fibrillation and sudden death. (aggarwal2024catecholaminergicpolymorphicventricular pages 1-2, aggarwal2024catecholaminergicpolymorphicventricular pages 2-4)

Age of onset: pediatric predominance, with mean onset in one review 7–12 years and >60% experiencing their first syncope/cardiac arrest by age 20. (aggarwal2024catecholaminergicpolymorphicventricular pages 1-2)

Episodic nature: events are often episodic and triggered, rather than continuously progressive; however, untreated disease is described as highly lethal with substantial pre-diagnosis syncope/cardiac arrest burden. (aggarwal2024catecholaminergicpolymorphicventricular pages 8-9)

Atrial arrhythmias and sinus node dysfunction: RYR2 mutation carriers can present with broader rhythm phenotypes (including sinoatrial node dysfunction and atrial arrhythmias), particularly in children. (wang2024clinicalcharacteristicsand pages 7-8)

3.2 Frequency among affected individuals (recent study statistics)

• In a 2024 Korean pediatric cohort (n=23), 73.9% developed cardiac events, 43.5% had aborted cardiac arrest, and 21.7% died during follow-up (mean follow-up 9.4±6.5 years). (lee2024treatmentoutcomesin pages 7-9)
• In a 2023 Chinese pediatric cohort/review of 95 children, 13 deaths were reported during the disease course; RYR2 variants were 70.1% of genotyped cases (47/67). (yan2023clinicalandgenetic pages 1-2)

3.3 Suggested HPO terms (non-exhaustive)

Based on reported phenotypes and triggers in the retrieved sources: - Syncope — HP:0001279 (aggarwal2024catecholaminergicpolymorphicventricular pages 1-2, jurisic2023catecholaminergicpolymorphicventricular pages 1-2) - Sudden cardiac arrest — HP:0001695 (lee2024treatmentoutcomesin pages 7-9) - Ventricular tachycardia (polymorphic/bidirectional) — HP:0004756 (aggarwal2024catecholaminergicpolymorphicventricular pages 1-2, peltenburg2024prognosisandclinical pages 1-2) - Premature ventricular contractions — HP:0001669 (peltenburg2024prognosisandclinical pages 1-2) - Atrial fibrillation/flutter — HP:0005110 / HP:0004799 (supported as atrial tachyarrhythmias occur in CPVT case series) (jurisic2023catecholaminergicpolymorphicventricular pages 1-2) - Sinus bradycardia / sinus node dysfunction — HP:0001688 / HP:0001642 (yan2023clinicalandgenetic pages 2-4, wang2024clinicalcharacteristicsand pages 7-8)

3.4 Quality of life impact

Quality-of-life impact is primarily mediated by exercise restriction, syncope risk, and ICD shock burden/psychological distress; LCSD is noted in review-level evidence as potentially improving quality of life by reducing events/shocks. (aggarwal2024catecholaminergicpolymorphicventricular pages 14-15)

4. Genetic / molecular information

4.1 Causal gene(s)

RYR2 is the predominant causal gene for CPVT1, accounting for roughly ~60–70% of cases in review summaries; cohort data in Chinese children showed 70.1% of genetically positive tests were RYR2. (aggarwal2024catecholaminergicpolymorphicventricular pages 1-2, aggarwal2024catecholaminergicpolymorphicventricular pages 2-4, yan2023clinicalandgenetic pages 1-2)

4.2 Variant characteristics

• Variant type: predominantly missense (~96% per one review), described as gain-of-function. (aggarwal2024catecholaminergicpolymorphicventricular pages 2-4)
• Penetrance: review summaries estimate ~75–80% for RYR2-mediated disease. (aggarwal2024catecholaminergicpolymorphicventricular pages 2-4)
• Variant distribution: RYR2 pathogenic variants often cluster in three regions (N-terminal, central, C-terminal), though rare variants occur in healthy individuals, complicating interpretation. (peltenburg2024prognosisandclinical pages 1-2)

Variant classification: Some cohorts explicitly reference ACMG/AMP variant classification (pathogenic/likely pathogenic/VUS), indicating clinical use of standardized classification frameworks in CPVT workups. (lee2024treatmentoutcomesin pages 7-9)

4.3 Modifier genes / multiple variants

A review notes that multiple variants are an independent predictor of adverse events in CPVT risk modeling. (aggarwal2024catecholaminergicpolymorphicventricular pages 8-9)

4.4 Epigenetics / chromosomal abnormalities

No RYR2-CPVT–specific epigenetic or chromosomal abnormality evidence was identified in the retrieved sources.

5. Environmental information

5.1 Environmental and lifestyle factors

Adrenergic stimuli (exercise, emotional stress) are the key real-world triggers. Lifestyle recommendations and exercise modification are embedded in treatment algorithms and management considerations. (aggarwal2024catecholaminergicpolymorphicventricular pages 1-2, aggarwal2024catecholaminergicpolymorphicventricular media 56a4a30c)

5.2 Infectious agents

No infectious etiology is implicated for CPVT in the retrieved sources.

6. Mechanism / pathophysiology (causal chain, upstream vs downstream)

6.1 Canonical causal chain (current consensus)

Upstream trigger: catecholaminergic stimulation (exercise/emotion) increases adrenergic drive. (aggarwal2024catecholaminergicpolymorphicventricular pages 1-2, peltenburg2024prognosisandclinical pages 1-2)

Molecular defect: RYR2 pathogenic variants predispose RyR2 to abnormal gating and diastolic SR Ca2+ leak. (peltenburg2024prognosisandclinical pages 1-2, keefe2023roleofca^2+ pages 8-9)

Downstream electrophysiology: increased cytosolic Ca2+ activates the sodium–calcium exchanger (NCX), generating net inward current that produces delayed afterdepolarizations (DADs) and triggered action potentials → ventricular ectopy → polymorphic/bidirectional VT → VF/sudden death. (peltenburg2024prognosisandclinical pages 1-2, keefe2023roleofca^2+ pages 8-9)

6.2 Upstream modulators and structural biology (2023–2024 developments)

RyR2 regulatory complex and phosphorylation: A 2023 review summarizes RyR2 regulation by PKA and CaMKII (e.g., CaMKII phosphorylation at S2814; PKA at S2808/2830) and links phosphorylation and disrupted regulatory binding (e.g., FKBP12.6/calstabin2) to increased RyR2 open probability and diastolic Ca2+ sparks/leak. (keefe2023roleofca^2+ pages 29-34, keefe2023roleofca^2+ pages 3-4)

Structural “primed” state and Rycal stabilization (2024): A 2024 Nature Communications structural study reports that CPVT-linked RyR2 variants and remodeled RyR2 in heart failure share a pathologic “primed” intermediate conformation associated with diastolic Ca2+ leak; “Rycal” drugs are described as reverting the primed state toward closed and reducing leak. The paper describes RyR2 channels as hyperphosphorylated/oxidized and depleted of calstabin-2 in heart failure, and frames a unified structural-physiological mechanism of leak across arrhythmogenic disorders. (miotto2024structuralbasisfor pages 1-2)

6.3 Suggested GO biological process / cellular component terms (examples)

• Regulation of cardiac muscle contraction by calcium ion signaling — GO:0010881 (mechanistically central to RyR2 dysfunction and EC coupling) (keefe2023roleofca^2+ pages 29-34)
• Ryanodine-sensitive calcium-release channel activity — GO:0005219 (RyR2 function) (peltenburg2024prognosisandclinical pages 1-2)
• Calcium ion transport into cytosol — GO:0060402 (SR Ca2+ release) (peltenburg2024prognosisandclinical pages 1-2)
• Sarcoplasmic reticulum membrane — GO:0033017 (RyR2 localization) (peltenburg2024prognosisandclinical pages 1-2)

6.4 Suggested Cell Ontology (CL) terms (examples)

Primary affected cell type is the cardiac muscle cell / cardiomyocyte (e.g., CL:0000746), as the pathophysiology centers on SR Ca2+ handling in cardiomyocytes. (peltenburg2024prognosisandclinical pages 1-2, miotto2024structuralbasisfor pages 1-2)

7. Anatomical structures affected

7.1 Organ and system level

Primary system: cardiovascular; primary organ: heart with electrophysiologic dysfunction rather than structural cardiomyopathy in typical CPVT presentation. (aggarwal2024catecholaminergicpolymorphicventricular pages 1-2)

7.2 Tissue/cell level

Primary tissue: cardiac muscle; primary cell type: cardiomyocytes with abnormal SR Ca2+ handling. (peltenburg2024prognosisandclinical pages 1-2)

7.3 Subcellular level

Key compartment: sarcoplasmic reticulum (SR) Ca2+ stores and the SR membrane-localized RyR2 channel complex. (peltenburg2024prognosisandclinical pages 1-2, keefe2023roleofca^2+ pages 29-34)

8. Temporal development

8.1 Onset

Most commonly in childhood/adolescence; mean onset 7–12 years in a 2024 review summary, with a majority presenting by age 20. (aggarwal2024catecholaminergicpolymorphicventricular pages 1-2)

8.2 Progression/course

Course is typically episodic and trigger-dependent. However, multiple studies highlight that delayed/missed diagnosis is common and can contribute to poor outcomes. In China, pediatric CPVT showed a mean diagnostic delay of 4.3±6.6 years in a 95-patient compilation. (yan2023clinicalandgenetic pages 1-2)

9. Inheritance and population

9.1 Epidemiology

• Prevalence: estimated at ~1 in 10,000 (review-level). (aggarwal2024catecholaminergicpolymorphicventricular pages 1-2)
• Contribution to sudden death: may account for up to ~15% of unexplained SCD in young people (review-level). (aggarwal2024catecholaminergicpolymorphicventricular pages 1-2)
• Autopsy-negative SUD: one review states ~12% of autopsy-negative sudden unexplained deaths in young individuals have been linked to CPVT. (aggarwal2024catecholaminergicpolymorphicventricular pages 8-9)

9.2 Inheritance

• RYR2-mediated CPVT is typically autosomal dominant. (aggarwal2024catecholaminergicpolymorphicventricular pages 2-4)

9.3 Penetrance/expressivity

• Penetrance estimates in reviews range roughly ~63–78% overall and ~75–80% for RYR2-mediated CPVT, consistent with variable expressivity and incomplete penetrance. (aggarwal2024catecholaminergicpolymorphicventricular pages 2-4)

10. Diagnostics

10.1 Clinical criteria and key tests

• Exercise stress testing is the principal diagnostic modality to unmask adrenergically mediated polymorphic/bidirectional ventricular ectopy in the setting of a structurally normal heart and typically normal baseline ECG. (aggarwal2024catecholaminergicpolymorphicventricular pages 1-2, aggarwal2024catecholaminergicpolymorphicventricular pages 6-8)
• Epinephrine infusion test is an alternative when exercise testing is not feasible; one review provides a protocol (starting 0.05–0.1 mcg/kg/min titrated to 0.20 mcg/kg/min) and notes low sensitivity (28%) but high specificity (98%) relative to exercise testing, using arrhythmia induction criteria including polymorphic VT and high PVC burden. (aggarwal2024catecholaminergicpolymorphicventricular pages 6-8)

10.2 Genetic testing approach

• Genetic testing for CPVT-susceptibility genes (including RYR2) is recommended for probands with a clinical CPVT diagnosis, alongside cascade screening of first-degree relatives. (aggarwal2024catecholaminergicpolymorphicventricular pages 6-8)
• Because rare RYR2 variants occur in healthy individuals, recent expert discussion emphasizes careful variant adjudication and multidisciplinary review; de novo status increases pathogenic likelihood. (peltenburg2024prognosisandclinical pages 1-2)

10.3 Differential diagnosis (limited by retrieved evidence)

The retrieved texts emphasize that CPVT can be misdiagnosed as neurologic events (e.g., seizures) due to syncope and that careful arrhythmia provocation testing is needed. Detailed differential diagnosis lists were not extracted from the current evidence set. (jurisic2023catecholaminergicpolymorphicventricular pages 1-2)

11. Outcome / prognosis

11.1 Natural history severity and pre-diagnosis burden

A 2024 review summarizes substantial pre-diagnosis burden: ~30% experiencing at least one cardiac arrest and up to 80% having syncope prior to diagnosis; mortality is reported as high (30–50% by age 35 in review-level summaries). (aggarwal2024catecholaminergicpolymorphicventricular pages 8-9)

11.2 Recent cohort outcome statistics (2023–2024)

In the 2024 Korean pediatric cohort (n=23): - 5-year cardiac event-free survival: 31.2% - 10-year overall survival: 73.1% - Marked improvement in those diagnosed since 2009 (no deaths in that subgroup), consistent with evolving implementation of combination therapy and procedural adjuncts. (lee2024treatmentoutcomesin pages 1-2, lee2024treatmentoutcomesin pages 7-9)

12. Treatment

Current real-world algorithm (review-derived)

A recent treatment algorithm emphasizes lifestyle modification, first-line non-selective beta-blockade, escalation to flecainide and/or LCSD for persistent arrhythmias, and reserving ICD for the highest-risk patients or refractory cases; the same figure stratifies approaches for symptomatic vs asymptomatic individuals. (aggarwal2024catecholaminergicpolymorphicventricular media 56a4a30c)

Table: This table summarizes the main evidence-based management strategies for RYR2-mediated CPVT, integrating current review-level evidence with recent real-world pediatric cohort data. It is useful for comparing mechanism, clinical use, quantitative outcomes, and limitations across medications and procedures.

12.1 Evidence-based therapies (key quantitative findings)

Beta-blockers: non-selective agents (especially nadolol) are preferred; review-level hazard ratios suggest higher arrhythmic risk with beta1-selective blockers compared with nadolol (HR 2.04 in symptomatic children; HR 5.8 in a 216-patient RYR2 cohort). (aggarwal2024catecholaminergicpolymorphicventricular pages 11-12)

Flecainide add-on: in the 2024 Korean pediatric cohort, beta-blocker + flecainide was associated with a large reduction in cardiac events vs beta-blocker alone (HR 0.08; 95% CI 0.02–0.38; p=0.002). (lee2024treatmentoutcomesin pages 7-9)

LCSD: multicenter observational evidence summarized in a 2024 review suggests a 92% reduction in mean annual event rate (3.4 to 0.5) and major cardiac events reduction (86% to 21% over ~37 months), with ~1/3 recurrence even on optimal medical therapy. (aggarwal2024catecholaminergicpolymorphicventricular pages 14-15, aggarwal2024catecholaminergicpolymorphicventricular pages 12-14)

ICD: evidence summarized in a 2024 review highlights high complication and shock burdens (e.g., 20–30% inappropriate shocks; high device complication rates; electrical storms), and concern that shocks may fail for VT and can worsen arrhythmia in CPVT; ICD is increasingly framed as last-resort after optimal medical and LCSD therapy. (aggarwal2024catecholaminergicpolymorphicventricular pages 14-15, aggarwal2024catecholaminergicpolymorphicventricular pages 15-16)

12.2 MAXO term suggestions (examples)

(Provided as ontology normalization suggestions; not validated from a MAXO database in the retrieved sources.) - Beta-adrenergic antagonist therapy — MAXO: beta blocker therapy (aggarwal2024catecholaminergicpolymorphicventricular pages 11-12) - Flecainide therapy — MAXO: antiarrhythmic drug therapy (aggarwal2024catecholaminergicpolymorphicventricular pages 11-12) - Left cardiac sympathetic denervation — MAXO: cardiac sympathetic denervation (aggarwal2024catecholaminergicpolymorphicventricular pages 14-15) - Implantable cardioverter-defibrillator placement — MAXO: implantable cardioverter defibrillator implantation (aggarwal2024catecholaminergicpolymorphicventricular pages 14-15)

12.3 Recent/experimental treatments and latest research (2023–2024)

RyR2 stabilizers (“Rycals”) and structural mechanism: 2024 structural work supports the concept of pharmacologic stabilization of RyR2 away from a leak-prone primed state, providing mechanistic grounding for RyR2-stabilizing small-molecule approaches. (miotto2024structuralbasisfor pages 1-2)

Genome editing (preclinical, 2024): AAV9-delivered, mutation-specific CRISPR/SaCas9 disruption of the mutant Ryr2 allele in R176Q/+ mice produced durable suppression of inducible ventricular arrhythmias at 6 weeks and out to 12 months, with favorable cardiac safety on serial echocardiography and histology; it also reduced Ca2+ spark frequency (e.g., from 8.0±1.6 toward 2.2±0.5 sparks/100 mm/s). (moore2024longtermefficacyand pages 6-9, moore2024longtermefficacyand pages 1-3)

13. Prevention

Secondary prevention: cascade family screening is highlighted as increasing detection of asymptomatic RYR2 variant carriers; guidance suggests these individuals often develop phenotype in the first two decades and may have low arrhythmic risk, but evidence-based monitoring/therapy timing remains limited. (peltenburg2024prognosisandclinical pages 1-2)

Tertiary prevention: optimal beta-blocker adherence, escalation to flecainide and LCSD, and cautious ICD deployment aim to prevent recurrent malignant arrhythmias and device-related harm. (aggarwal2024catecholaminergicpolymorphicventricular pages 14-15, aggarwal2024catecholaminergicpolymorphicventricular pages 11-12)

14. Other species / natural disease

No naturally occurring veterinary CPVT information was retrieved in the current evidence set.

15. Model organisms / disease models

15.1 Mammalian genetic models

Ryr2 R176Q/+ mouse model is used for CPVT mechanistic and therapeutic studies; allele-specific AAV9-CRISPR editing in this model demonstrated durable antiarrhythmic efficacy and safety signals through 12 months. (moore2024longtermefficacyand pages 1-3, moore2024longtermefficacyand pages 6-9)

15.2 Human cellular models (in vitro)

Human iPSC-cardiomyocyte models engineered to carry CPVT-linked RYR2 variants demonstrate arrhythmogenic Ca2+ handling phenotypes; for example, CRISPR-introduced RyR2-S4938F in hiPSC-CMs is associated with altered Ca2+ signaling and increased spontaneous Ca2+ sparks/transients consistent with an arrhythmogenic phenotype. (toth2023calciumsignalingconsequences pages 1-2)

Recent developments and active clinical trials (ClinicalTrials.gov)

1) SGT-501 gene therapy in CPVT (NCT07148089) - Sponsor: Solid Biosciences; Phase 1b, open-label dose-finding; Recruiting; estimated enrollment 18. - Key inclusion: central-lab confirmed pathogenic/likely pathogenic RYR2 variant and prior life-threatening ventricular arrhythmic event; stable beta-blocker and/or flecainide regimen. - Primary endpoint: treatment-emergent adverse events through Day 360; secondary endpoint includes change in ventricular arrhythmia score (VAS) on exercise stress test at Day 180. Long-term follow-up planned for 5 years. (posted/record date in excerpt: 2026-04-03). URL: https://clinicaltrials.gov/study/NCT07148089 (NCT07148089 chunk 1, NCT07148089 chunk 2)

2) S48168 (ARM210) RyR2 modulator trial in CPVT1 (NCT05122975) - Sponsor: RyCarma Therapeutics; Phase 2, randomized crossover, quadruple-masked; enrollment 8; Terminated due to recruitment challenges. - Intervention: oral S48168 (ARM210) vs placebo on top of standard of care, 28-day periods. - Primary endpoint: change in exercise ectopy score from baseline to Day 28 vs placebo; additional endpoints include safety, PK, and wearable monitoring. Start date 2023-08-01; primary completion 2024-04-01. URL: https://clinicaltrials.gov/study/NCT05122975 (NCT05122975 chunk 1)

Direct quotes from abstracts (supporting key statements)

• Diagnostic hallmark and phenotype: “Diagnosing CPVT typically involves unmasking the arrhythmia through exercise stress testing… in the absence of structural heart disease… and with a normal baseline electrocardiogram.” (Aggarwal et al., 2024-03; URL https://doi.org/10.3390/jcm13061781) (aggarwal2024catecholaminergicpolymorphicventricular pages 1-2)

• Asymptomatic carrier management gap: asymptomatic family members with a pathogenic RYR2 variant have arrhythmic risk described as “presumably low” and phenotype “seems to develop in the first two decades of life,” with limited guidance. (Peltenburg et al., 2024-04; URL https://doi.org/10.1017/s1047951124000714) (peltenburg2024prognosisandclinical pages 1-2)

• Structural mechanism: RyR2 variants “linked either to heart failure or inherited sudden cardiac death… are in the primed state… Binding of Rycal drugs… reverts the primed state back towards the closed state, decreasing Ca2+ leak… preventing arrhythmias.” (Miotto et al., 2024-09; URL https://doi.org/10.1038/s41467-024-51791-y) (miotto2024structuralbasisfor pages 1-2)

Key limitations / evidence gaps

• Formal database identifiers (OMIM/Orphanet/MeSH/ICD/MONDO) were not retrievable within the current evidence set; a dedicated database lookup would be required to populate those fields with citations.
• Several important quantitative claims in review articles summarize prior cohorts/meta-analyses; the underlying primary sources (often pre-2023) were not all retrieved as full text in this run, limiting direct PMID-level citation.
• Differential diagnosis lists, QoL instrument data (EQ-5D/SF-36/PROMIS), and protective genetic/environmental factors were not found in the retrieved evidence.

URLs and publication dates (selected high-priority sources used)

• Aggarwal et al. “Catecholaminergic Polymorphic Ventricular Tachycardia: Clinical Characteristics, Diagnostic Evaluation and Therapeutic Strategies.” J Clin Med (2024-03). https://doi.org/10.3390/jcm13061781 (aggarwal2024catecholaminergicpolymorphicventricular pages 1-2)
• Peltenburg et al. “Prognosis and clinical management of asymptomatic family members with RYR2-mediated CPVT.” Cardiol Young (2024-04). https://doi.org/10.1017/S1047951124000714 (peltenburg2024prognosisandclinical pages 1-2)
• Lee et al. “Treatment outcomes in children with CPVT: a single institutional experience.” Korean Circ J (2024-12). https://doi.org/10.4070/kcj.2024.0183 (lee2024treatmentoutcomesin pages 1-2)
• Yan et al. “Clinical and genetic profiles of Chinese pediatric CPVT patients.” Orphanet J Rare Dis (2023-12). https://doi.org/10.1186/s13023-023-02991-0 (yan2023clinicalandgenetic pages 1-2)
• Miotto et al. “Structural basis for RyR2 leak…” Nat Commun (2024-09). https://doi.org/10.1038/s41467-024-51791-y (miotto2024structuralbasisfor pages 1-2)
• Moore et al. “Long-term efficacy and safety of cardiac genome editing for CPVT.” J Cardiovasc Aging (2024-01). https://doi.org/10.20517/jca.2023.42 (moore2024longtermefficacyand pages 1-3)
• ClinicalTrials.gov NCT07148089 (SGT-501 gene therapy) record excerpt date 2026-04-03. https://clinicaltrials.gov/study/NCT07148089 (NCT07148089 chunk 1)
• ClinicalTrials.gov NCT05122975 (S48168/ARM210) start 2023-08-01; primary completion 2024-04-01. https://clinicaltrials.gov/study/NCT05122975 (NCT05122975 chunk 1)

References

1. (aggarwal2024catecholaminergicpolymorphicventricular pages 1-2): Abhinav Aggarwal, Anton Stolear, Md Mashiul Alam, Swarnima Vardhan, Maxim Dulgher, Sun-Joo Jang, and Stuart W. Zarich. Catecholaminergic polymorphic ventricular tachycardia: clinical characteristics, diagnostic evaluation and therapeutic strategies. Journal of Clinical Medicine, 13:1781, Mar 2024. URL: https://doi.org/10.3390/jcm13061781, doi:10.3390/jcm13061781. This article has 27 citations.

2. (peltenburg2024prognosisandclinical pages 1-2): Puck J. Peltenburg, Harry Gibson, Arthur A. M. Wilde, Christian van der Werf, Sally-Ann B. Clur, and Nico A. Blom. Prognosis and clinical management of asymptomatic family members with ryr2-mediated catecholaminergic polymorphic ventricular tachycardia: a review. Cardiology in the young, 34:1-8, Apr 2024. URL: https://doi.org/10.1017/s1047951124000714, doi:10.1017/s1047951124000714. This article has 1 citations and is from a peer-reviewed journal.

3. (lee2024treatmentoutcomesin pages 1-2): Joowon Lee, Bo Sang Kwon, Mi Kyoung Song, Sang-Yun Lee, Jung Min Ko, Gi Beom Kim, and Eun Jung Bae. Treatment outcomes in children with catecholaminergic polymorphic ventricular tachycardia: a single institutional experience. Korean Circulation Journal, 54:853-864, Dec 2024. URL: https://doi.org/10.4070/kcj.2024.0183, doi:10.4070/kcj.2024.0183. This article has 1 citations and is from a peer-reviewed journal.

4. (jurisic2023catecholaminergicpolymorphicventricular pages 1-2): Stjepan Jurisic, Argelia Medeiros-Domingo, Florian Berger, Christian Balmer, Corinna Brunckhorst, Frank Ruschitzka, Ardan M. Saguner, and Firat Duru. Catecholaminergic polymorphic ventricular tachycardia: multiple clinical presentations of a genetically determined disease. Journal of Clinical Medicine, 13:47, Dec 2023. URL: https://doi.org/10.3390/jcm13010047, doi:10.3390/jcm13010047. This article has 5 citations.

5. (aggarwal2024catecholaminergicpolymorphicventricular pages 2-4): Abhinav Aggarwal, Anton Stolear, Md Mashiul Alam, Swarnima Vardhan, Maxim Dulgher, Sun-Joo Jang, and Stuart W. Zarich. Catecholaminergic polymorphic ventricular tachycardia: clinical characteristics, diagnostic evaluation and therapeutic strategies. Journal of Clinical Medicine, 13:1781, Mar 2024. URL: https://doi.org/10.3390/jcm13061781, doi:10.3390/jcm13061781. This article has 27 citations.

6. (aggarwal2024catecholaminergicpolymorphicventricular pages 6-8): Abhinav Aggarwal, Anton Stolear, Md Mashiul Alam, Swarnima Vardhan, Maxim Dulgher, Sun-Joo Jang, and Stuart W. Zarich. Catecholaminergic polymorphic ventricular tachycardia: clinical characteristics, diagnostic evaluation and therapeutic strategies. Journal of Clinical Medicine, 13:1781, Mar 2024. URL: https://doi.org/10.3390/jcm13061781, doi:10.3390/jcm13061781. This article has 27 citations.

7. (aggarwal2024catecholaminergicpolymorphicventricular pages 8-9): Abhinav Aggarwal, Anton Stolear, Md Mashiul Alam, Swarnima Vardhan, Maxim Dulgher, Sun-Joo Jang, and Stuart W. Zarich. Catecholaminergic polymorphic ventricular tachycardia: clinical characteristics, diagnostic evaluation and therapeutic strategies. Journal of Clinical Medicine, 13:1781, Mar 2024. URL: https://doi.org/10.3390/jcm13061781, doi:10.3390/jcm13061781. This article has 27 citations.

8. (wang2024clinicalcharacteristicsand pages 7-8): Yefeng Wang, Yufan Yang, Ningan Xu, Yunbin Xiao, Chao Zuo, and Zhi Chen. Clinical characteristics and follow-up of complex arrhythmias associated with ryr2 gene mutations in children. Frontiers in Genetics, May 2024. URL: https://doi.org/10.3389/fgene.2024.1405437, doi:10.3389/fgene.2024.1405437. This article has 1 citations and is from a peer-reviewed journal.

9. (lee2024treatmentoutcomesin pages 7-9): Joowon Lee, Bo Sang Kwon, Mi Kyoung Song, Sang-Yun Lee, Jung Min Ko, Gi Beom Kim, and Eun Jung Bae. Treatment outcomes in children with catecholaminergic polymorphic ventricular tachycardia: a single institutional experience. Korean Circulation Journal, 54:853-864, Dec 2024. URL: https://doi.org/10.4070/kcj.2024.0183, doi:10.4070/kcj.2024.0183. This article has 1 citations and is from a peer-reviewed journal.

10. (yan2023clinicalandgenetic pages 1-2): Yu Yan, Liting Tang, Xiaoqin Wang, Kaiyu Zhou, Fan Hu, Hongyu Duan, Xiaoliang Liu, Yimin Hua, and Chuan Wang. Clinical and genetic profiles of chinese pediatric patients with catecholaminergic polymorphic ventricular tachycardia. Orphanet Journal of Rare Diseases, Dec 2023. URL: https://doi.org/10.1186/s13023-023-02991-0, doi:10.1186/s13023-023-02991-0. This article has 4 citations and is from a peer-reviewed journal.

11. (yan2023clinicalandgenetic pages 2-4): Yu Yan, Liting Tang, Xiaoqin Wang, Kaiyu Zhou, Fan Hu, Hongyu Duan, Xiaoliang Liu, Yimin Hua, and Chuan Wang. Clinical and genetic profiles of chinese pediatric patients with catecholaminergic polymorphic ventricular tachycardia. Orphanet Journal of Rare Diseases, Dec 2023. URL: https://doi.org/10.1186/s13023-023-02991-0, doi:10.1186/s13023-023-02991-0. This article has 4 citations and is from a peer-reviewed journal.

12. (aggarwal2024catecholaminergicpolymorphicventricular pages 14-15): Abhinav Aggarwal, Anton Stolear, Md Mashiul Alam, Swarnima Vardhan, Maxim Dulgher, Sun-Joo Jang, and Stuart W. Zarich. Catecholaminergic polymorphic ventricular tachycardia: clinical characteristics, diagnostic evaluation and therapeutic strategies. Journal of Clinical Medicine, 13:1781, Mar 2024. URL: https://doi.org/10.3390/jcm13061781, doi:10.3390/jcm13061781. This article has 27 citations.

13. (aggarwal2024catecholaminergicpolymorphicventricular media 56a4a30c): Abhinav Aggarwal, Anton Stolear, Md Mashiul Alam, Swarnima Vardhan, Maxim Dulgher, Sun-Joo Jang, and Stuart W. Zarich. Catecholaminergic polymorphic ventricular tachycardia: clinical characteristics, diagnostic evaluation and therapeutic strategies. Journal of Clinical Medicine, 13:1781, Mar 2024. URL: https://doi.org/10.3390/jcm13061781, doi:10.3390/jcm13061781. This article has 27 citations.

14. (keefe2023roleofca^2+ pages 8-9): Joshua A. Keefe, Oliver M. Moore, Kevin S. Ho, and Xander H. T. Wehrens. Role of ca^2+ in healthy and pathologic cardiac function: from normal excitation–contraction coupling to mutations that cause inherited arrhythmia. Archives of Toxicology, 97:73-92, Oct 2023. URL: https://doi.org/10.1007/s00204-022-03385-0, doi:10.1007/s00204-022-03385-0. This article has 45 citations and is from a highest quality peer-reviewed journal.

15. (keefe2023roleofca^2+ pages 29-34): Joshua A. Keefe, Oliver M. Moore, Kevin S. Ho, and Xander H. T. Wehrens. Role of ca^2+ in healthy and pathologic cardiac function: from normal excitation–contraction coupling to mutations that cause inherited arrhythmia. Archives of Toxicology, 97:73-92, Oct 2023. URL: https://doi.org/10.1007/s00204-022-03385-0, doi:10.1007/s00204-022-03385-0. This article has 45 citations and is from a highest quality peer-reviewed journal.

16. (keefe2023roleofca^2+ pages 3-4): Joshua A. Keefe, Oliver M. Moore, Kevin S. Ho, and Xander H. T. Wehrens. Role of ca^2+ in healthy and pathologic cardiac function: from normal excitation–contraction coupling to mutations that cause inherited arrhythmia. Archives of Toxicology, 97:73-92, Oct 2023. URL: https://doi.org/10.1007/s00204-022-03385-0, doi:10.1007/s00204-022-03385-0. This article has 45 citations and is from a highest quality peer-reviewed journal.

17. (miotto2024structuralbasisfor pages 1-2): Marco C. Miotto, Steven Reiken, Anetta Wronska, Qi Yuan, Haikel Dridi, Yang Liu, Gunnar Weninger, Carl Tchagou, and Andrew R. Marks. Structural basis for ryanodine receptor type 2 leak in heart failure and arrhythmogenic disorders. Nature Communications, Sep 2024. URL: https://doi.org/10.1038/s41467-024-51791-y, doi:10.1038/s41467-024-51791-y. This article has 40 citations and is from a highest quality peer-reviewed journal.

18. (aggarwal2024catecholaminergicpolymorphicventricular pages 11-12): Abhinav Aggarwal, Anton Stolear, Md Mashiul Alam, Swarnima Vardhan, Maxim Dulgher, Sun-Joo Jang, and Stuart W. Zarich. Catecholaminergic polymorphic ventricular tachycardia: clinical characteristics, diagnostic evaluation and therapeutic strategies. Journal of Clinical Medicine, 13:1781, Mar 2024. URL: https://doi.org/10.3390/jcm13061781, doi:10.3390/jcm13061781. This article has 27 citations.

19. (lee2024treatmentoutcomesin pages 6-7): Joowon Lee, Bo Sang Kwon, Mi Kyoung Song, Sang-Yun Lee, Jung Min Ko, Gi Beom Kim, and Eun Jung Bae. Treatment outcomes in children with catecholaminergic polymorphic ventricular tachycardia: a single institutional experience. Korean Circulation Journal, 54:853-864, Dec 2024. URL: https://doi.org/10.4070/kcj.2024.0183, doi:10.4070/kcj.2024.0183. This article has 1 citations and is from a peer-reviewed journal.

20. (aggarwal2024catecholaminergicpolymorphicventricular pages 12-14): Abhinav Aggarwal, Anton Stolear, Md Mashiul Alam, Swarnima Vardhan, Maxim Dulgher, Sun-Joo Jang, and Stuart W. Zarich. Catecholaminergic polymorphic ventricular tachycardia: clinical characteristics, diagnostic evaluation and therapeutic strategies. Journal of Clinical Medicine, 13:1781, Mar 2024. URL: https://doi.org/10.3390/jcm13061781, doi:10.3390/jcm13061781. This article has 27 citations.

21. (lee2024treatmentoutcomesin pages 9-10): Joowon Lee, Bo Sang Kwon, Mi Kyoung Song, Sang-Yun Lee, Jung Min Ko, Gi Beom Kim, and Eun Jung Bae. Treatment outcomes in children with catecholaminergic polymorphic ventricular tachycardia: a single institutional experience. Korean Circulation Journal, 54:853-864, Dec 2024. URL: https://doi.org/10.4070/kcj.2024.0183, doi:10.4070/kcj.2024.0183. This article has 1 citations and is from a peer-reviewed journal.

22. (aggarwal2024catecholaminergicpolymorphicventricular pages 15-16): Abhinav Aggarwal, Anton Stolear, Md Mashiul Alam, Swarnima Vardhan, Maxim Dulgher, Sun-Joo Jang, and Stuart W. Zarich. Catecholaminergic polymorphic ventricular tachycardia: clinical characteristics, diagnostic evaluation and therapeutic strategies. Journal of Clinical Medicine, 13:1781, Mar 2024. URL: https://doi.org/10.3390/jcm13061781, doi:10.3390/jcm13061781. This article has 27 citations.

23. (aggarwal2024catecholaminergicpolymorphicventricular pages 16-18): Abhinav Aggarwal, Anton Stolear, Md Mashiul Alam, Swarnima Vardhan, Maxim Dulgher, Sun-Joo Jang, and Stuart W. Zarich. Catecholaminergic polymorphic ventricular tachycardia: clinical characteristics, diagnostic evaluation and therapeutic strategies. Journal of Clinical Medicine, 13:1781, Mar 2024. URL: https://doi.org/10.3390/jcm13061781, doi:10.3390/jcm13061781. This article has 27 citations.

24. (moore2024longtermefficacyand pages 6-9): Oliver M. Moore, Y. Aguilar-Sánchez, S. Lahiri, M. Hulsurkar, J. Navarro-Garcia, Tarah A. Word, Joshua A. Keefe, Dean Barazi, Elda Munivez, Charles T. Moore, Vaidya Parthasarathy, Jaysón M. Davidson, W. Lagor, So Hyun Park, Gang Bao, Christina Y Miyake, X. Wehrens, OM Moore, WR Lagor, Wehrens Xht, SK Lahiri, MM Hulsurkar, J. Navarro-Garcia, Tarah A. Word, JA Keefe, CT Moore, Parthasarathy Barazi D, SH Park, and CY Miyake. Long-term efficacy and safety of cardiac genome editing for catecholaminergic polymorphic ventricular tachycardia. The Journal of Cardiovascular Aging, Jan 2024. URL: https://doi.org/10.20517/jca.2023.42, doi:10.20517/jca.2023.42. This article has 11 citations.

25. (moore2024longtermefficacyand pages 1-3): Oliver M. Moore, Y. Aguilar-Sánchez, S. Lahiri, M. Hulsurkar, J. Navarro-Garcia, Tarah A. Word, Joshua A. Keefe, Dean Barazi, Elda Munivez, Charles T. Moore, Vaidya Parthasarathy, Jaysón M. Davidson, W. Lagor, So Hyun Park, Gang Bao, Christina Y Miyake, X. Wehrens, OM Moore, WR Lagor, Wehrens Xht, SK Lahiri, MM Hulsurkar, J. Navarro-Garcia, Tarah A. Word, JA Keefe, CT Moore, Parthasarathy Barazi D, SH Park, and CY Miyake. Long-term efficacy and safety of cardiac genome editing for catecholaminergic polymorphic ventricular tachycardia. The Journal of Cardiovascular Aging, Jan 2024. URL: https://doi.org/10.20517/jca.2023.42, doi:10.20517/jca.2023.42. This article has 11 citations.

26. (toth2023calciumsignalingconsequences pages 1-2): Noemi Toth, Xiao-Hua Zhang, Alexandra Zamaro, and Martin Morad. Calcium signaling consequences of ryr2-s4938f mutation expressed in human ipsc-derived cardiomyocytes. International Journal of Molecular Sciences, 24:15307, Oct 2023. URL: https://doi.org/10.3390/ijms242015307, doi:10.3390/ijms242015307. This article has 3 citations.

27. (NCT07148089 chunk 1): A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). Solid Biosciences Inc.. 2026. ClinicalTrials.gov Identifier: NCT07148089

28. (NCT07148089 chunk 2): A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). Solid Biosciences Inc.. 2026. ClinicalTrials.gov Identifier: NCT07148089

29. (NCT05122975 chunk 1): Treatment of an Inherited Ventricular Arrhythmia. RyCarma Therapeutics, Inc.. 2023. ClinicalTrials.gov Identifier: NCT05122975